{
  "docId": "019de076-0bfb-77a4-9766-824e83d61c36",
  "docSlug": "78f42e9d8d70fea2dc2370a17955f7e7",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 52,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes clinical trial data cut-offs and patient enrollment numbers.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-0bfb-77a4-9766-824e83d61c36/27",
  "deckHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36",
  "deckJsonHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36.json",
  "deckAnchorHref": "/decks/019de076-0bfb-77a4-9766-824e83d61c36#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.48,
        "x": 0.439,
        "y": 0.8
      },
      "kind": "callout",
      "text": "ARROS-1 update expected at a medical meeting in 2024",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d02f1016-a5e2-4db3-ad66-1782f75399d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.34,
        "x": 0.082,
        "y": 0.238
      },
      "kind": "diagram",
      "text": "Preliminary Phase 1 Dose Escalation Data: Data cut-off: September 13, 2022 35 ROS1+ patients enrolled across five dose levels (25 mg QD – 125 mg QD) Source: Drilon et al., EORTC-NCI-AACR 2022\nUpdated Phase 1 Data Shared with FDA: Data cut-off: May 17, 2023 87 ROS1+ patients enrolled across six dose levels (25 mg QD – 150 mg QD)",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41cbc433-66cd-4f35-b7ea-ea9b24e3e401",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.35,
        "x": 0.075,
        "y": 0.895
      },
      "kind": "disclaimer",
      "text": "CNS, Central Nervous System; MTD, Maximum Tolerated Dose; QD, Once Daily.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1d530348-4a6d-41cc-b153-7971d10b7455",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.48,
        "x": 0.439,
        "y": 0.285
      },
      "kind": "list",
      "text": "Overall, the company believes these findings to be consistent with the preliminary Phase 1 conclusions reported in October 2022\nFavorable tolerability of NVL-520 was observed across all dose levels to date\nMTD was not reached, and no clinically significant exposure-response relationships for safety and efficacy were observed across the dose levels evaluated (25 mg – 150 mg daily)\nThe dose level of 100 mg daily maintained steady state plasma levels above all target efficacy thresholds (ROS1 wild type and ROS1 G2032R in both the periphery and in the CNS)\nAlignment with FDA on RP2D selection",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "732b492f-a8b7-46ac-a37b-442ddaa82214",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.35,
        "x": 0.439,
        "y": 0.238
      },
      "kind": "paragraph",
      "text": "Rationale for Selection of 100 mg as RP2D",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2626d18d-415e-47ce-9a8e-56fff9f49ce9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.86,
        "x": 0.07,
        "y": 0.11
      },
      "kind": "title",
      "text": "100 mg QD Selected as Recommended Phase 2 Dose (RP2D) for NVL-520",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce79d6df-87ac-40e9-8a16-47b7fbd53741",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 45,
      "from": 13,
      "beatId": "11ad9310-8f34-4e49-9752-09ee2f990465",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 13-45: Various traction slides, including preclinical and clinical trial results",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}